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Summary
We identified dynein light chain 1 (DLC1) as a physiologic substrate of p21-activated kinase 1 (Pak1). Pak1-DLC1 interaction
plays an essential role in cell survival, which depends on Pak1’s phosphorylation of DLC1 on Ser88. Pak1 associates with
the complex of DLC1 and BimL, a proapoptotic BH3-only protein, and phosphorylates both proteins. Phosphorylation of
BimL by Pak1 prevents it from interacting with and inactivation of Bcl-2, an antiapoptotic protein. Overexpression of DLC1
but not DLC1-Ser88Ala mutant promotes cancerous properties of breast cancer cells. DLC1 protein level is elevated in
more than 90% of human breast tumors. The regulation of cell survival functions by Pak1-DLC1 interaction represents a
novel mechanism by which a signaling kinase might regulate the cancerous phenotypes.
Introduction (T423), within the activation loop of the kinase (Daniels and
Bokoch, 1999). Expression of an activated Pak1 mutant (T423E)
triggers the dissolution of stress fibers and focal adhesion com-The p21-activated kinases (Paks), an evolutionarily conserved
family of serine/threonine kinases, are essential for a variety of plexes, the formation of lamellipodia (Manser et al., 1997), and
reorganization of actin cytoskeleton. Some of the effects ofcellular functions, including cell morphogenesis, cell motility,
cell survival, angiogenesis, and mitosis (Bokoch, 2003; Kumar Pak1 on the actin cytoskeleton appear to be independent of
Pak1 kinase activity but dependent on protein-protein interac-and Vadlamudi, 2002). At present, the Pak family consists of
six members, Pak1 through Pak6. Pak1 has been identified as tions (Turner et al., 1999). However, kinase activity is important
for directional motility (Sells et al., 2000). Nonetheless, Pak1one of the targets of the activated Rho GTPases Cdc42 and
Rac1, which stimulate Pak autophosphorylation and activity mutants with defective GTPase binding sites or kinase activity
retain the ability to induce the formation of membrane ruffles(Manser et al., 1994). Stimulation of Pak1 activity results in
several phenotypic changes reminiscent of those produced by and filopodia (Sells et al., 1997; Frost et al., 1998). Pak1 also
stimulates LIM kinase (LIMK) activity and, in turn, increasesCdc42 and Rac1 (Sells et al., 1997; Vadlamudi et al., 2000; Li
et al., 2002; Thiel et al., 2002). Paks are widely expressed in phosphorylation and inactivation of cofilin, leading to reduction
in the depolymerization of actin filaments (Edwards and Gill,numerous tissues and are activated by a number of polypeptide
factors and extracellular signals in both a GTPase-dependent 1999; Edwards et al., 1999). Pak1 has been shown to influence
cell survival by phosphorylating Bad (Schurmann et al., 2000),manner via Rac1 or Cdc42 and a GTPase-independent manner
via its localization to membrane/focal adhesion (Bokoch et al., and overexpression of Paks in cancer cells increases cell migra-
tion potential and anchorage-independent growth and causes1996; Bagrodia and Cerione, 1999; Zhao et al., 2000). Paks are
also activated by lipids (Bokoch et al., 1998), tyrosine kinases abnormalities in mitosis (Banerjee et al., 2002; Li et al., 2002).
However, the molecular mechanisms by which Pak1 regulates(McManus et al., 2000; Bagheri-Yarmand et al., 2001), novel
substrates such as filamin (Vadlamudi et al., 2002), and G pro- cell growth and cell survival functions remain elusive.
Dynein light chain 1 (DLC1), an 8 kDa component of theteins (Lian et al., 2001).
The activation of Pak1 by diverse signals leads to its auto- cytoplasmic dynein complex (Hirokawa, 1998), is highly con-
served among species, is widely expressed in a number ofphosphorylation at multiple sites, including threonine 423
S I G N I F I C A N C E
There is increasing evidence that p21-activated kinase 1 (Pak1) and dynein light chain 1 (DLC1), both components of the cytoskeleton
system, target different pathways to support cell survival. However, no DLC1 function has been associated with its phosphorylation,
and no signaling kinase has been shown to phosphorylate DLC1. We found that DLC1 is a physiologic interacting substrate of Pak1
and that the Pak1-DLC1 interaction is essential to its cell survival functions. We have discovered that deregulation of DLC1, but not
its Pak1 phosphorylation mutant, confers cell survival, anchorage independence, and tumorigenesis in nude mice and that DLC1
is widely overexpressed in human breast tumors. Thus, DLC1 can function as a tumor promoter and requires active Pak1 signaling.
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tissues, and is localized predominantly in the cytoplasm. In stimulation (Figure 1C). Similarly, immunoprecipitation of the
endogenous DLC1 along with a catalytically active Pak1 (HA-addition to playing an essential role in dynein motor function,
DLC1 interacts with a number of proteins with diverse functions. tagged T423E Pak1) further confirmed the existence of Pak1-
DLC1 interaction in vivo (Figure 1D). In brief, these findingsFor example, DLC1 associates with neuronal nitric oxide syn-
thase (nNOS) and inhibits its activity and proapoptotic function strongly suggested that Pak1 interacts with DLC1 in a physio-
logically relevant setting.in neuronal cells; hence, DLC1 has also been referred to as
protein inhibitor of NOS (PIN) (Jaffrey and Snyder, 1996). DLC1
also interacts and interferes with the proapoptotic Bcl-2 family DLC1 interacts with Pak1 via its C-terminal region
We next mapped the DLC1 binding site in Pak1 using the GSTprotein BimL (Puthalakath et al., 1999; Puthalakath and Strasser,
2002). Although the functional role of DLC1 in cell survival has fusion domains of Pak1 (Figure 2A). Results showed that the
Pak1 amino acids (aa) 132–270, but not aa 1–132, efficientlybeen observed, no function of DLC1 has been assigned to its
phosphorylation, and no upstream signaling kinase has been interacted with DLC1. Furthermore, the Cdc42/Rac interactive
binding (CRIB) domain (aa 53–132), the Pak1 autoinhibitory do-shown to phosphorylate DLC1 and influence these functional
outcomes. main (aa 75–149), and the kinase domain of Pak1 (aa 270–545)
did not interact with DLC1, suggesting that the binding sitesTo identify novel Pak1 binding proteins, we performed a
yeast two-hybrid screen of the mammary gland cDNA expres- for DLC1 are localized within the aa 150–270 of Pak1. Earlier
studies showed that the Pak1 aa 150–270 region contains thesion library using Pak1 N-terminal amino acids 1–270 as a bait.
We identified DLC1 as a Pak1-interacting protein. We showed PIX binding site (a noncanonical proline-rich region, aa 192–203)
(Daniels et al., 1999). Therefore, to further examine whether thethat DLC1 is a physiologic, interacting substrate of Pak1. The
Pak1-DLC1 interactions play an essential role in the cell-survival DLC1 binding region in Pak1 overlaps with the PIX binding site,
we created additional fine deletions in this region (Figure 2B).functions of both Pak1 and DLC1, and the underlying mecha-
nism involves Pak1’s phosphorylation of DLC1 on serine 88 GST protein containing the PIX binding domain (aa 182–203)
showed no interaction with DLC1, suggesting that the Pak1(Ser88). Unexpectedly, we discovered that DLC1 expression is
commonly elevated in human breast tumors and that deregula- binding site does not overlap with the PIX binding site. However,
GST fusion containing Pak1 aa 203–270 showed distinct bindingtion of DLC1, but not DLC1 mutant lacking Ser88, promotes
the tumorigenic potential of breast cancer cells. The regulation to DLC1, implying that the DLC1 binding site in Pak1 is localized
to the 67 amino acid region spanning aa 203–270 of Pak1.of cell survival and tumorigenic functions by Pak1-DLC1 interac-
tion represents a novel mechanism by which a signaling kinase Next, using a series of DLC1 deletion constructs, we identi-
fied the minimal region of DLC1 required for its interaction withmight control these essential processes in cancer cells.
Pak1. As illustrated in Figure 2C, deletion of N-terminal regions
had no effect on Pak1 binding, whereas deletion of theResults
C-terminal 22 amino acids (aa 67–89) completely abolished
Pak1 binding (Figure 2C, lanes 6 and 7). GST fusion of DLC1Pak1 interacts with DLC1
A yeast two-hybrid screening of the mammary gland cDNA C-terminal 19 amino acids alone was sufficient for Pak1 binding
(Figure 2C, lane 5), suggesting that the Pak1 binding site inexpression library was performed to identify Pak1-interacting
proteins using the Pak1 N-terminal amino acids 1–270 as bait. DLC1 is in the C terminus.
This bait contains several protein binding motifs that differ from
one Pak family member to another. This analysis resulted in the DLC1 is a physiological substrate of Pak1
To determine whether DLC1 is a substrate of Pak1, we exploredidentification of a substantial number of known Pak1 binding
proteins (i.e., Cdc42, Rac1, Pix, and Nck) and several previously the possibility that DLC1 could be phosphorylated in vivo by
physiologic signals, such as EGF, that activate Pak1 (Kumaruncharacterized Pak1-interacting proteins. Sequence analysis
of several isolates from one of the novel interacting clones was and Vadlamudi, 2002). MCF-7 cells were metabolically labeled
with [32P]orthophosphoric acid and stimulated with EGF, andidentical to that of DLC1 (GenBank accession number
NM_003746). The specificity of the Pak1-DLC1 interactions was DLC1 was immunoprecipitated with an anti-DLC1 antibody. The
autoradiogram showed a substantial increase in the level ofverified by cotransfection of Pak1 and DLC1 plasmids into the
yeast cells (Figure 1A). Cotransfection of DLC1 with the Pak1 DLC1 phosphorylation in EGF-treated cells (Figure 3A). To ex-
amine the specific role of Pak1 in growth factor-mediated phos-N-terminal amino acids 1–270 but not control vector enabled
the transformed colonies to grow in medium lacking adenosine, phorylation of DLC1, we used an siRNA specific to Pak1 (Wang
et al., 2002) to selectively knock down its expression. Introduc-histidine, leucine, and tryptophan (AHLT) and reacted positively
in -galactosidase assay (Figure 1A). tion of Pak1 siRNA in MCF-7 cells resulted in 70% reduction
in the level of Pak1 protein and was accompanied by a 60%To verify the specificity of the Pak1-DLC1 interaction, we
next evaluated the ability of in vitro translated Pak1 protein to reduction in the ability of EGF to stimulate DLC1 phosphoryla-
tion compared with its activity in control cells (Figure 3A, lanebind with the DLC1-GST fusion protein. The DLC1-GST fusion
protein, but not GST, efficiently interacted with 35S-labeled full- 3). To independently validate these findings, we repeated the
experiment using a Pak1 autoinhibitory fragment, Pak1 aa 83–length Pak1 protein (Figure 1B, left). Conversely, in vitro trans-
lated 35S-labeled DLC1 protein specifically interacted with the 149, a well-established inhibitor of Pak1 (Vadlamudi et al., 2002).
MCF-7 cells were transiently transfected with T7-tagged DLC1GST-Pak1 (Figure 1B, right). The in vivo interaction of the endog-
enous DLC1 with Pak1 was confirmed by immunoprecipitation with or without the Pak1 inhibitory fragment. As shown in Figure
3B, EGF treatment rapidly stimulated DLC1 phosphorylation inof Pak1 and DLC1 using lysates from MCF-7 breast cancer
cells treated with or without epidermal growth factor (EGF), a Pak1-sensitive manner, and it was substantially blocked by
coexpression of Pak1 autoinhibitory fragment aa 83–149. Next,and results show that Pak1 interacted with DLC1 upon ligand
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Figure 1. Identification of DLC1 as a Pak1 binding
protein
A: Yeast cells were cotransfected with control
GAD vector or GAD-DLC1, GAD-Rac1 along with
GBD vector, or GBD-Pak1 (aa 1–270) or GBD-
Pak1 (aa 271–545). Cotransformants were plated
on selection plates lacking leucine and trypto-
phan (LT) or adenosine, histidine, leucine, and
tryptophan (AHLT). Growth was recorded after
72 hr. For -galactosidase assay, filter lift assays
were performed (middle). Blue color indicates
specific interaction of two proteins. Rac1 was
used as a positive control.
B: Pak1 and DLC1 interaction in the GST pull-
down assays. DLC1 or Pak1 cDNAs were trans-
lated in vitro, and 35S-labeled proteins were incu-
bated with either GST-Pak1 or GST-DLC1 and
analyzed by SDS-PAGE and autoradiography.
C: In vivo interaction of Pak1 with endogenous DLC1. MCF-7 cells were serum starved for 48 hr and treated with epidermal growth factor (EGF) for 30 min,
and cell lysates were immunoprecipitated with either Pak1 or DLC1 antibody. DLC1 association was analyzed by Western blotting with Pak1 or DLC1
antibody.
D: Activated Pak1 interacts with DLC1. Tet on-vector or Tet on-HA-Pak1-T423E expressing MCF-7 cells grown in 10% serum were lysed, and lysates containing
equal amounts of protein were immunoprecipitated with HA antibody and immunoblotted with antibodies against DLC1 and Pak1.
we examined whether expression of catalytically active Pak1 (Figure 3C), suggesting a role of Pak1 in the phosphorylation
of DLC1 in vivo.(Pak1T423E) would mimic EGF-mediated DLC1 phosphoryla-
tion. MCF-7 cells were cotransfected with T7-tagged DLC1 and To map the Pak1 phosphorylation site in DLC1, we per-
formed in vitro kinase assays using GST-DLC1 as a substrate.myc-tagged constitutively active T423E Pak1 or kinase dead
Pak1 K299R and labeled with [32P]orthophosphoric acid. Immu- The BAD, a well-known Pak1 substrate, was used as a positive
control. The Pak1 enzyme efficiently phosphorylated GST-DLC1noprecipitation of DLC1 with an anti-T7 monoclonal antibody
showed increased phosphorylation of DLC1 in cells expressing as well as BAD (Figure 3D). We next mapped the Pak1 phosphor-
ylation site in DLC1 using various deletion constructs of DLC1.myc-T423E Pak1 but not in cells expressing myc-K299R Pak1
GST fusion containing the C-terminal 19 amino acids of DLC1
alone was efficiently phosphorylated by Pak1 (Figure 3E, lane
5), suggesting the presence of a putative phosphorylation site
in the C-terminal region. Analysis of the C-terminal 19 amino
acids sequence revealed one serine at amino acid 88. Deletion
of two C-terminal amino acids of DLC1 (aa 88 and aa 89) com-
pletely abolished the ability of Pak1 to phosphorylate DLC1
(Figure 3E, lane 7). To confirm these findings, we substituted
Ser88 to alanine (DLC1 Ser88A). As expected from the deletion
studies, Pak1 failed to phosphorylate DLC1 Ser88A, confirming
that Pak1 phosphorylates DLC1 on Ser88 (Figure 3F). To verify
that Ser88 is the only DLC1 site that is phosphorylated by growth
factors in vivo, we performed a transient transfection experiment
with wild-type and Ser88A mutants of DLC1 (Figure 3G). Muta-
tion of Ser88 on DLC1 to alanine completely abolished growth
factor-mediated phosphorylation of DLC1. Collectively, these
observations confirmed that DLC1 is a physiologic substrate of
Pak1 and that Ser88 on DLC1 is the Pak1 phosphorylation site.
DLC1 regulation of cell growth
To further delineate the potential effects of DLC1 on the biologyFigure 2. Mapping of interaction domains of Pak1 and DLC1
of breast cancer cells, we next examined the status of DLC1A: Identification of Pak1 domains that interact with DLC1. GST-Pak1 fusion
proteins containing wild-type (aa 1–545), kinase domain (aa 271–545), expression in a number of breast cancer cell lines. Breast cancer
N-terminal domain (aa 1–132), PIX binding domain (aa 182–203), Nck bind- cells contained a higher level of DLC1 than nontumorigenic
ing domain (aa 1–75), Cdc42/Rac-interactive binding (CRIB) domain (aa
breast cancer cell lines, such as MCF10A and HC11 (Figure 4A).52–132), and autoinhibitory domain (aa 75–149) were incubated with in vitro
Because the ZR75 cells showed lower levels of DLC1 expressiontranslated DLC1 (aa 1–89), and binding was analyzed by GST pull-down
assay. than other breast cancer cell lines used here, we next estab-
B: GST pull-down assay in lanes 9–13 shows various deletions of Pak1 in the lished stable ZR75 pooled clones expressing T7-tagged wild-
region of 132–270. type DLC1 or mutant DLC1del88–89 or control vector (Figure 4B).C: Identification of the DLC1 region involved in the binding of Pak1. GST
In general, these clones contained DLC1 levels 2- to 4-foldfusions of various lengths of DLC1 were used in the GST pull-down assay
using 35S-labeled Pak1 (amino acids 1–545). higher than the endogenous level of DLC1. Because both Pak1
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Figure 3. Pak1 phosphorylation of DLC1
A: MCF-7 cells were transfected with Pak1-specific or control siRNA, metabolically labeled with [32P]orthophosphoric acid, and treated with or without EGF.
Endogenous DLC1 was immunoprecipitated, and the phosphorylation status of DLC1 was analyzed by autoradiography. Total lysates were analyzed for
Pak1, Pak2, and vinculin by Western blotting.
B: MCF-7 cells were transfected with T7-DLC1 with or without Pak1 autoinhibitory domain (Pak1 aa 83–149). Cells were metabolically labeled with [32P]ortho-
phosphoric acid and treated with or without EGF (1 nM) for 1 hr; then the phosphorylation of T7-DLC1 was analyzed by autoradiography.
C: MCF-7 cells were cotransfected with wild-type T7-DLC1 and T423E-Pak1 or K299R-Pak1. Cells were metabolically labeled with [32P]orthophosphoric acid.
T7-DLC1 was immunoprecipitated, and the phosphorylation status was visualized by autoradiography.
D: In vitro kinase assay using GST-DLC1 as a substrate and purified bacterially expressed Pak1 as an enzyme. GST was used as negative control, and His-
BAD was used as a positive control.
E: In vitro Pak1 kinase assay using GST fusion of DLC1 fragments containing the indicated serial deletions of DLC1.
F: In vitro Pak1 kinase assay using DLC1 wild-type or mutant DLC1S88A as substrates.
G: MCF-7 cells transfected with wild-type DLC1 or mutant DLC1S88A were labeled in vivo with [32P]orthophosphoric acid, serum starved, treated with EGF
for 60 min, and immunoprecipitated; then phosphorylation status of DLC1 or its mutant was visualized by autoradiography.
and DLC1 are both shown to have a role in cell growth and Interference with this Pak1-DLC1 pathway might trigger sponta-
neous apoptosis.survival (Puthalakath et al., 1999; Chang et al., 2000; Schurmann
et al., 2000), we next examined whether Pak1 and DLC1 interac-
An essential role of DLC1 in Pak1-mediated cell survivaltion have a role in cell growth and cell survival pathways. Inter-
Earlier studies have shown that Pak family kinases protect mu-estingly, deregulated DLC1 expression increased the prolifera-
rine NIH3T3 cells from ultraviolet (UV)-induced apoptosis (Ja-tion rate of the ZR75 cells (Figure 4C). The increased proliferation
kobi et al., 2001). Using this well-established model system, weof the ZR75 cells could have reflected either an increased prolif-
next investigated the potential role of Pak1-DLC1 interaction ineration rate or protection of the cells from apoptosis. Flow cy-
protecting NIH3T3 cells against UV-induced apoptosis. NIH3T3tometry analysis of serum-starved ZR75 clones revealed that
cells were cotransfected with RFP-tagged DLC1 or the mutantderegulation of wild-type DLC1, but not mutant DLC1del88-89, was
Ser88A DLC1 and catalytically active Pak1 (myc-T423E Pak1)accompanied by increased G1→S progression of breast cancer
or kinase-dead Pak1 (myc-K299LL Pak1), and cells were ex-cells. Interestingly, ZR75 cells expressing DLC1del88-89 exhibited
posed to UV irradiation. After 10 hr, apoptosis was quantitateda significant increase in the number of cells in the pre-G0 phase
by scoring the integrity of the nuclear membrane in cells ex-
of the cell cycle (Figure 4D). Consistent with a potential role of
pressing both RFP (red) and myc-epitope tags to detect DLC1
DLC1 in the G1/S transition, we found an increased expression and Pak1, respectively (Figure 5A). Results indicated that UV-
of cyclin E in the clones with deregulated DLC1 but not in induced apoptosis was substantially reduced in cells expressing
control pcDNA clones (Figure 4E). Further analysis using CDK2 DLC1 and catalytically active Pak1 but not in Ser88A DLC1
phospho-specific antibody revealed a substantial enhancement or kinase-dead Pak1 or the combination of these (Figure 5A).
of CDK2 phosphorylation in DLC1 expressing clones. In addi- Interestingly, overexpression of active Pak1 could not protect
tion, biochemical analysis of the cyclin E immunocomplex con- the cells transfected with the mutant Ser88A DLC1. Similarly,
firmed the presence of elevated CDK2 kinase activity in the overexpression of DLC1 failed to protect the NIH3T3 cells over-
DLC1 clones, as well as increased phosphorylation of pRb at expressing the kinase-dead Pak1 from UV-induced apoptosis
Ser795, a known CDK2/cyclin E phosphorylation site (Figure (Figure 5A).
4E). These findings provided clues about a potential role of As an additional evidence of a role of DLC1 in the cell survival
and a broader significance of our findings in human cells inPak1-mediated DLC1 phosphorylation in optimal cell survival.
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Figure 4. DLC1 expression and cell growth
A: Expression of DLC1 in a number of normal and
breast cancer cells analyzed by Western blot
analysis.
B: Expression of T7-DLC1 wild-type or T7-
DLC1del88-89 in stable clones analyzed by Western
blot analysis.
C: Equal number of ZR75 stable cells expressing
DLC1 wild-type or DLC1del88-89 mutant were cul-
tured. At indicated intervals, cells were trypsin-
ized and counted using a Coulter Counter to
determine cell proliferation. Each clone was
plated in triplicate, and the experiment was re-
peated twice with similar results.
D: Cell cycle status of DLC1 wild-type, mutant,
and pcDNA clones as analyzed by flow cytom-
etry.
E: pcDNA and DLC1 stable clones were analyzed
by Western blotting for the levels of cyclin E (left),
for the levels of phospho CDK2 (middle) and the
activity of CDK2 by immunoprecipitation fol-
lowed by in vitro kinase assay using histone H1
as substrate, and also by Western blotting of total
lysate using phospho pRb Ser795-specific anti-
body (right).
general, we next downregulated Pak1 in IMR-90 human fibro- phosphorylated with Pak1 enzyme and subjected to the GST
pull-down assay with 35S-labeled BimL. Our results suggestblasts by transiently expressing GFP vector or GFP vector ex-
pressing Pak1-siRNA. In some cultures, cells were cotrans- that unphosphorylated but not phosphorylated DLC1 efficiently
interacts with BimL, raising the possibility that Pak1 phosphory-fected with GFP-tagged dominant active Pak1-T423E along
with control or DLC-specific siRNA (Figure 5B). After 48 hr, cells lation might interfere with the ability of DLC1 to interact with
BimL (Figure 6A). To confirm these observations, we next mu-were exposed to UV (100 J/m2). The onset of apoptosis was
monitored by scoring the nuclear integrity using lamin A/C anti- tated the Pak1 phosphorylation site Ser88 either to alanine or
glutamic acid. GST pull-down assays showed that a Ser88 tobody. GFP staining was used to localize the positive transfected
cells. We found that as expected, expression of activated Pak1 alanine mutation has no effect on BimL binding to DLC1 (Figure
6B). However, a Ser88 to glutamic acid mutation, which mimicsincreased the cell survival after UV exposure, while knockdown
of the expression of DLC1 resulted in a substantial increase in the phosphorylated form of DLC1 due to the addition of negative
charge, abolished DLC1 interaction with BimL. Similarly, dele-the ratio of apoptotic cells after UV damage. Interestingly, the
noticed apoptotic response due to lack of DLC1 could not be tion of the C-terminal amino acids 88 and 89, which contain
Ser88, also abolished BimL binding (Figure 6C). These resultsrescued by activated Pak1 (Figure 5C). These findings suggest
that Pak1-DLC1 interactions play an important role in their sur- support the earlier view that DLC1 interacts with BimL via the
C-terminal region (Puthalakath et al., 1999) and now offers anvival functions.
additional regulatory role of the Pak1 phosphorylation of DLC1.
In normal physiologic conditions, BimL is sequestered byPak1-DLC1 interaction promotes cell survival
by blocking BimL’s apoptotic functions DLC1, and DLC1-BimL dimers are released upon stimulation
of cells with apoptotic stimuli. The DLC1-BimL dimers thenBecause DLC1 is known to interact and sequester proapoptotic
BimL in the cytoplasm (Puthalakath et al., 1999) and because interact with Bcl-2 and thus inhibit cell survival functions of
Bcl-2 (Puthalakath et al., 1999; Puthalakath and Strasser, 2002).Pak1 phosphorylates DLC1 in the region that interacts with
BimL (Puthalakath et al., 1999), we next examined whether Pak1 Therefore, we next explored whether Pak1 recognizes DLC1-
BimL dimers. Results from the GST pull-down studies demon-phosphorylation of BimL interferes with BimL apoptotic func-
tions. Initially, we examined the effect of Pak1 phosphorylation strated that Pak1 recognizes DLC1 as well as DLC1 bound to
BimL (Figure 6D). We then examined whether apoptotic signalson the ability of DLC1 to interact with BimL. GST-DLC1 was
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Figure 5. Requirement of DLC1 and Pak1 interac-
tion for cell survival
A: Immunofluorescence staining of NIH3T3 cells
cotransfected with various combinations of
DLC1 wild-type or DLC1S88A mutant and various
Pak1 constructs, exposed to UV radiation 100
mJ/s and after 10 hr, costained for myc-tag (for
Pak1 constructs, blue), RFP-DLC1 wild-type, or
mutants (DLC1 constructs, red) and for lamin A/C
(green). Cells expressing the transfected plas-
mids were identified using appropriate filter set-
tings and then characterized for their nuclear
integrity using morphologic features identified by
lamin A/C staining. For example, a smooth nu-
clear membrane was scored as nonapoptotic
as opposed to membrane blebbing or rupture,
which was scored as apoptotic. Nuclei commit-
ted to enter mitosis were not scored in either of
these groups because they were easily identified
for their specific “pulverized” pattern of lamin
A/C staining. Ten randomly selected fields were
analyzed for each condition. The experiment
was repeated twice with similar results.
B: Functionality of DLC siRNA was analyzed by
Western analysis.
C: Immunofluorescence staining of IMR90 hu-
man fibroblast cells cotransfected with GFP-
tagged T423E Pak1 or GFP-tagged Pak1 siRNA
or DLC1 siRNA or in combination. After 48 hr, cells
were exposed to UV radiation 100 mJ/s and after
10 hr, costained for GFP-Pak1T423E (green), GFP-
Pak1 siRNA (green), or endogenous DLC1 (blue)
and for lamin A/C (red). Apoptotic cells were
scored as described in (A). Yellow arrow points
to an apoptotic cell and white arrow points to
a cell that was protected by expression of active
Pak1.
such as UV and survival signals such as EGF modulate the the levels of BimL expression via its phosphorylation and thus
counteract proapoptotic functions of BimL (Ley et al., 2003;status of phosphorylation of DLC1 and BimL. UV treatment
alone did not induce phosphorylation of DLC1 or BimL; rather, Luciano et al., 2003; Reginato et al., 2003; Seward et al., 2003).
Because growth factors activate Pak1 (Kumar and Vadlamudi,a slight decrease in the phosphorylation was observed com-
pared to control (Figure 6E). Interestingly, the addition of survival 2002) and because Pak1 phosphorylated BimL in this study,
we next examined the effect of Pak1 activation on the status offactors such as EGF followed by UV treatment resulted in a
substantial increase in the phosphorylation of both DLC1 and BimL expression using a well-established Tet-inducible MCF-7
model system (Vadlamudi et al., 2000). Treatment of cells withBimL. Transfection of cells with Pak1 inhibitory domain (Pak1
aa 83–149) effectively inhibited the noticed upregulation of BimL doxycycline induced the levels of constitutively active Pak1 in
a time-dependent manner. Analysis of BimL expression underphosphorylation by EGF under condition of UV treatment (data
not shown), suggesting an additional regulatory role of Pak1 in this condition showed a decrease in the expression of BimL
levels with an increase in the expression of active Pak1 (FigureBimL phosphorylation. In support of this notion, we next found
that Pak1 could indeed directly phosphorylate BimL (Figure 6F). 6H). As a positive control, we analyzed the status of cyclin D1
expression, which is known to be upregulated by Pak1 (Balasen-We then examined whether Pak1 phosphorylates BimL when
present as a dimer with DLC1 and when attached to the dynein thil et al., 2004). As expected, cyclin D1 expression was upregu-
lated with an increase in active Pak1 levels. To examine whethercomplex via dynein intermediate chain (DIC) as a trimeric com-
plex (DIC-DLC1-BimL) using in vitro Pak1 kinase assay. Results Pak1 kinase activity indeed is involved in the downregulation
of BimL, we transfected activated Pak1 (T423E Pak1) or GTPaseshow that Pak1 preferentially phosphorylates BimL present in
the dimeric form (DLC1-BimL) compared to BimL present in inactive kinase-dead Pak1 (LLK299R) into MCF-7 cells, and the
expression of BimL was analyzed after 48 hr. Our results showedtrimeric form (DIC-DLC1-BimL) (Figure 6G).
Physiologic cell survival signals are known to downregulate a decrease in the level of BimL expression in cells with activated
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Figure 6. Pak1 phosphorylation regulates BimL and DLC1 interactions
A: Effect of Pak1 phosphorylation on the binding of DLC1 with BimL. GST-DLC1 was phosphorylated with Pak1 enzyme, and the GST pull-down assay was
performed using phosphorylated GST-DLC1 or wild-type GST-DLC1. Autoradiogram showing the phosphorylation of DLC1 is shown in the right panel.
B: Ability of DLC1-Ser88A or DLC1-Ser88E mutants to interact with BimL in GST pull-down assay.
C: Ability of GST-DLC1 (aa 1–87) to interact with BimL was analyzed by GST pull-down assay.
D: Ability of Pak1 to interact with DLC1-BimL dimers. 35S-labeled DLC1 and BimL were incubated with GST-Pak1, and GST pull-down assay was performed.
E: MCF-7 cells were labeled with 32P-orthophosphoric acid, and cells were treated with UV or pretreated with EGF (100 ng/ml) followed by UV treatment.
Cell lysates were immunoprecipitated with antibodies against DLC1 or BimL, and the phosphorylation status of proteins was analyzed by autoradiography.
F: Phosphorylation of GST-BimL by Pak1 in in vitro kinase assay.
G: Purified GST-BimL was incubated with purified beads bound GST-DLC1 along with or without purified GST-dynein intermediate chain proteins. After 60
min of incubation, dimeric and trimeric complexes were purified by GST-DLC1 pull-down assay and used as a substrate in in vitro Pak1 kinase assay.
H: Downregulation of BimL levels by constitutively active Pak1. MCF-7 cells expressing T423E-Pak1 under the control of Tet-regulated promoter were treated
with doxycycline for 12 or 24 hr. Expression of BimL, cyclin D1, and HA-tagged T423E Pak1 was analyzed by Western blotting.
I: MCF-7 cells were transiently transfected with CMV vector or constitutively active Pak1 (CMV-myc-T423EPak1) or kinase-dead Pak1 (CMV-myc-LLK299Rpak1).
After 48 hr of transfection, cell lysates were analyzed for BimL expression. Actin was used as a loading control. Myc-epitope antibody was used to monitor
the expression of myc-tagged Pak1 constructs.
J: Model for Pak1 regulation of DLC1 and BimL functions. Under physiologic conditions, DLC1 sequesters BimL to the microtubules. Under apoptotic conditions,
DLC1-BimL dimers are released and interact with Bcl-2. Survival factors activate Pak1, which in turn phosphorylates DLC1-BimL dimers and, thus, prevents
BimL interaction with Bcl-2.
Pak1 but not in kinase-dead Pak1, suggesting Pak1 kinase growth of breast cancer cells (Vadlamudi et al., 2000), we exam-
ined the ability of the ZR75/DLC1 clones to grow in an anchor-activity is involved in the downregulation of BimL expression
(Figure 6I). These findings suggested a mechanistic role of DLC1 age-independent manner. DLC1 wild-type but not the DLC1
mutant expression substantially enhanced the number of colo-Ser88 phosphorylation in conferring a survival advantage by
modulating the levels of DLC1-BimL dimers, which are dissoci- nies in soft agar (Figure 7A), suggesting a role of DLC1 in anchor-
age-independent growth.ated upon apoptotic signaling and, thus, may have a role in
enhanced cell survival and, consequently, increased growth rate To examine the potential correlation of DLC1 deregulation
with the progression of breast cancer to more aggressive pheno-(Figure 6J).
types, we next analyzed DLC1 expression in lysates from expo-
nentially growing cell lines derived from the MCF10AT modelDeregulation of DLC1 promotes tumorigenesis
system. This model contains a spectrum of cell lines that allowsBecause DLC1 expression promoted G1→S transition as well
as cell survival (Figures 4C and 4D) and because Pak1 overex- us to examine the expression of genes during the progression
of breast malignancy (Heppner et al., 2000; Santner et al., 2001).pression is known to support the anchorage-independent
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Figure 7. DLC1 deregulation potentiates anchor-
age-independent growth and promotes tumori-
genesis
A: Effect of DLC1 wild-type or mutant overex-
pression on the ability of ZR75 cells to grow in an
anchorage-independent manner. The anchor-
age-independent growth potential of DLC1-
expressing clones was measured by the ability
of the cells to form colonies on soft agar. Similar
results were obtained in three independent ex-
periments. Error bars represent standard error of
mean.
B: Western blot analysis of DLC1 and Pak1 levels
in lysates from cells derived from MCF10AT model
system. MCF10A, nonmalignant human breast
cancer cells; MCF10AT, weakly tumorigenic;
MCF10DCIS, Comedo-type DCIS, highly prolifer-
ative, aggressive, invasive; and MCF10CA, undif-
ferentiated carcinomas, metastatic.
C: Nude mice were injected with 5  106 cells
stably expressing pcDNA or wild-type DLC1
(pooled clone #2) or mutant pooled clone
DLC1del88-89, and tumor growth was measured at
weekly intervals.
D: A representative picture of DLC1-induced tu-
mor in nude mice. Tumor growth was observed
only in cells expressing wild-type DLC1 but not
detected in mutant-expressing cells.
E: Morphology of tumor and expression of T7-
DLC1 in tumors as evaluated by hematoxylin and
eosin and anti-T7 staining, respectively.
Figure 7B shows a clearly progressive upregulation of DLC1 al., 2004), we found that 34 out of 60 specimens had over-
expressed both Pak1 and DLC1. To examine whether DLC1expression as a function of tumorigenesis. Consistent with the
protein in tumors is phosphorylated, we have used a recentlyaggressive growth characteristics of the DLC1-expressing
available phospho-serine-specific antibody, which specificallybreast cancer cells, the ZR/DLC1 cells (pooled clone 2) exhibited
recognizes serine-phosphorylated proteins (Gronborg et al.,increased tumorigenic potential in nude mice in the absence of
2002). We have used an affinity column of this antibody to purifyany exogenous estradiol treatment (Figures 7C and 7D), sug-
serine-phosphorylated proteins from the human breast tumorsgesting that deregulation of DLC1 might be sufficient to promote
and adjacent normal tissues. Elutes from columns were precipi-tumorigenic phenotypes. Interestingly, DLC1 mutant lacking the
tated and then Western blotted with DLC1-specific antibody.Pak1 phosphorylation site did not exhibit any tumorigenic po-
As a proof of principle, we have analyzed six normal and sixtential in nude mice (Figure 7C). The clonal origin of T7-DLC1-
tumor samples. Results showed that five out of six tumors havederegulated cells from tumors was confirmed by staining the
more serine-phosphorylated form of DLC1 compared to controlcells with an anti-T7 monoclonal antibody (Figure 7E). These
(Figure 8E). These results further support our hypothesis thatfindings suggested the existence of a close relationship between
increased DLC1 protein expression in tumors also translates intoDLC1 deregulation and its phosphorylation by Pak1 and tumori-
its more phosphorylated form. Together, results from Figures 7genesis.
and 8 suggested that deregulation of DLC1 and Pak1 might be
a common event in cancer progression and that these molecules
DLC1 upregulation in human breast cancer may be involved in the development and/or maintenance of the
We next examined the level of DLC1 in 15 paired samples of malignant phenotypes in tumors.
human breast tumors and adjacent normal tissues. The status
of DLC1 expression was considerably higher in 14 out of 15 Discussion
breast tumor specimens than in adjacent normal tissues (Figures
8A and 8B). The anti-DLC1 antibody also works well in formalin- In this study, we discovered that DLC1 is a Pak1-interacting
fixed, paraffin-embedded human breast tissues, as shown in a protein. This conclusion is supported by the ability of Pak1 to
representative DLC1 immunohistochemical (IHC) staining (Fig- interact with DLC1 in yeast two-hybrid, in GST pull-down, and in
ure 8C). Further IHC examination of a tumor array containing reciprocal immunoprecipitation assays. Furthermore, our results
60 breast tumor specimens revealed widespread upregulation show that DLC1 is a physiologic substrate of Pak1. We have
of DLC1 expression in 54 out of 60 breast tumors (Figure 8D). identified Ser88 of DLC1 as the Pak1 phosphorylation site and
Because breast tumor specimens used here have recently been demonstrated an essential role of this pathway in growth factor-
mediated cell survival.characterized for the levels of Pak1 expression (Balasenthil et
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inhibition of apoptosis (Dick et al., 1996). In human cells, DLC1
interacts with BimL and promotes cell survival by inhibiting its
proapoptotic activity (Puthalakath et al., 1999). In addition,
cyclooxygenase 2 promotes cell survival by stimulating DLC1
expression and inhibiting the neuronal NO pathway (Chang et
al., 2000). Under physiologic conditions, BimL is sequestered
to dynein motor via the DIC-DLC1-BimL complex (Puthalakath
et al., 1999; Puthalakath and Strasser, 2002). Apoptotic stimuli
release dimer-containing DLC1-BimL, which then translocates
and interacts with Bcl-2, leading to the inactivation of the anti-
apoptotic function of Bcl-2 and promotion of the apoptotic func-
tion of BimL. Growth factors have been shown to increase phos-
phorylation and degradation of BimL and thus modulate the
apoptotic functions of BimL. Although the mechanism by which
growth factors regulate BimL functions remains elusive, emerg-
ing evidence suggests a role of phosphorylation in the degrada-
tion of BimL by growth factors (Ley et al., 2003; Luciano et al.,
2003; Seward et al., 2003). In this context, our findings that
Pak1 phosphorylates BimL and that activated Pak1 reduces
BimL levels are important because they suggest that Pak1 might
act as a downstream effector of growth factor-mediated modu-
Figure 8. DLC1 deregulation in human breast tumors lation of BimL levels. The ability of Pak1 to recognize and phos-
A: Breast tumor lysates were analyzed by Western blot analysis for DLC1 phorylate DLC1-BimL dimer also strongly supports the possi-
expression (top) and subsequently reprobed with vinculin antibody as a bility that Pak1 acts as a growth factor sensor to detect the
loading control. DLC1-BimL dimers generated by apoptotic signals and that
B: Quantitation of DLC1 expression in normal and tumor samples.
Pak1 might dissociate these complexes via phosphorylation.C: Immunohistochemical analysis of DLC1 in breast tissue samples. The left
Emerging evidence implies that Pak1 might play an impor-panel shows normal mammary gland tissue, and the right panel shows
tumor from the same patient. Tumor shows very strong nuclear and cyto- tant role in tumorigenesis (Kumar and Vadlamudi, 2002). Dereg-
plasmic DLC1 immunoreactivity. ulation of Pak1 expression is reported in breast and ovarian
D: Quantitation of DLC1 expression in breast tumor array.
cancers (Vadlamudi et al., 2000; Balasenthil et al., 2004; SchramlE: Phosphorylation of DLC1 in normal and tumor samples. Serine phosphory-
et al., 2003). We showed that Pak1 interacted with DLC1 andlated proteins in normal and tumor lysates (2 mg) were purified using phos-
phoserine purification kit (Qiagen) as described in Experimental Procedures, that such interactions are essential for cell cycle progression
and purified proteins were precipitated using trichloroacetic acid. Levels and survival functions. Accordingly, overexpression of DLC1
of DLC1 in the precipitate were then measured by Western blotting using
substantially increased the growth potential of the breast cancerDLC1-specific antibody.
cells, allowing the cells to survive in an anchorage-independent
manner and exhibit increased tumorigenic potential of breast
cancer cells. Interestingly, DLC1 and Pak1 expression levels
were more elevated in breast tumors than in normal controlDLC1 is ubiquitously expressed in different cell types and
specimens, raising the possibility that DLC1 has a role in tumori-highly conserved throughout evolution. DLC1 is not only associ-
genesis.ated with myosin V (Naisbitt et al., 2000) and dynein (Hirokawa,
In summary, our results showed that DLC1 is an interacting1998) motors, but it also binds to nNOS (Jaffrey and Snyder,
substrate of Pak1, that DLC1 is overexpressed in human breast1996; Fan et al., 1998), the proapoptotic Bcl-2 family protein
cancers, and that Pak1 phosphorylation of DLC1 on Ser88 playsBimL (Puthalakath et al., 1999), the Drosophila mRNA localiza-
a critical role in tumorigenic phenotypes of DLC1 in breast can-tion protein Swallow (Schnorrer et al., 2000), transcriptional reg-
cer cells.ulator IkB (Crepieux et al., 1997), and the postsynaptic scaffold
protein GKAP (Naisbitt et al., 2000). These observations suggest
Experimental procedures
that DLC1 is a multifunctional regulatory protein. Previously
structural studies have shown that DLC1 exists as a dimer and Cell cultures, reagents, transfection, and cell extracts
MCF-7 breast cancer cells (Vadlamudi et al., 2000) were maintained in Dul-contains two identical target binding grooves on the opposite
becco’s modified Eagle’s medium (DMEM)-F12 (1:1) supplemented withfaces of the protein dimer interface (Fan et al., 2001). In this
10% fetal calf serum. Antibodies DLC1 were purchased from Santa Cruzcontext, DLC1 has been suggested to function as a linker protein
Biotechnology (Santa Cruz, CA) and BD Biosciences (San Jose, CA). Anti-
by binding two different proteins (Liang et al., 1999). The ability body against T7 was purchased from Novagen (Milwaukee, WI). BimL anti-
of DLC1 to interact with proteins with diverse cellular functions body was purchased from Chemicon (Melbourne, Australia). Antibodies for
suggests that DLC1, in principle, might recruit Pak1 to other Pak1, phos Ser795 pRb, Phos CDK2, and siRNA against Pak1 (#6361) and
control FITC siRNA (#6201) were purchased from Cell Signaling (Boston,signaling proteins.
MA). SMART POOL siRNA for DLC1 and DLC2 was synthesized by Dhar-Pak1 has been shown to promote cell survival by phosphory-
macon (Lafayette, CO). Transient transfection studies were performed usinglating and inactivating the proapoptotic functions of Bad (Schur-
a FuGENE-6 kit (Roche Molecular Biochemicals, Indianapolis, IN) in accor-
mann et al., 2000). Overexpression of a constitutively active dance with the manufacturer’s instructions. Cell lysates were resolved on
T423E Pak1 mutant promotes the survival of NIH3T3 murine an 18% tricine gels. ZR75 cells were transfected with pcDNA3.1, pcDNA-
T7-DLC1, or dsREDGFP-DLC1 via the calcium phosphate method. Forty-fibroblasts. Similar to Pak1, Drosophila DLC1 plays a role in the
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eight hours after transfection, cells were selected in medium containing Immunohistochemistry
For immunohistochemical detection of DLC1 and T7, sections were deparaf-G418 (500 g/ml).
finized with xylene and rehydrated using graded ethanol. Sections were
incubated in 0.3% H2O2 and methanol for 30 min to inactivate endogenousTwo-hybrid library screening and plasmid construction
peroxidase. The sections were then boiled for 10 min in 0.01 M citrate bufferPak1 baits were constructed by amplifying amino acids 1–270 and amino
and cooled for 30 min at room temperature to expose antigenic epitopes.acids 271–545 by polymerase chain reaction (PCR) and then subcloned
The sections were incubated with 2% normal goat serum in 1% bovineinto Gal4 binding domain vector pGBD vector (Clontech, Palo Alto, CA). A
serum albumin and PBS for 30 min and then with an anti-DLC1 antibodymammary gland cDNA library fused to Gal4 activation domain was pur-
(1:50 dilution) or anti-T7 antibody (1:800 dilution) and incubated overnightchased from Clontech and screened using N-terminal Pak1 (aa 1–270) as
at room temperature. The sections were washed 3 times with 0.05% Tweenbait in accordance with the manufacturer’s instructions. A total of 2 
in PBS for 10 min and incubated with secondary antibody, developed with106 clones were screened. Positive interactors were verified by one-on-
DAB-H2O2, and counter stained with Mayer’s hematoxylin.one transformations followed by selection of agar plates lacking adenosine,
histidine, leucine, and tryptophan (AHLT) and also by -galactosidase assay.
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